# Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

> **NCT02389517** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 42 (actual)

## Conditions studied

- Plasma Cell Myeloma
- Residual Disease

## Interventions

- **DRUG:** Ixazomib Citrate
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02389517
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-02
- **Primary completion:** 2021-02
- **Final completion:** 2024-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-01-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389517, "Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT02389517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*